Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Phenylephrine | The risk or severity of hypertension can be increased when Loteprednol is combined with Phenylephrine. |
| Aminoglutethimide | The therapeutic efficacy of Loteprednol can be decreased when used in combination with Aminoglutethimide. |
| Insulin human | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin human. |
| Insulin lispro | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin lispro. |
| Insulin glargine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin glargine. |
| Insulin pork | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin pork. |
| Troglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Troglitazone. |
| Glimepiride | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Glimepiride. |
| Sulfisoxazole | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sulfisoxazole. |
| Disopyramide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Disopyramide. |
| Acarbose | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Acarbose. |
| Metformin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Metformin. |
| Sulfadiazine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sulfadiazine. |
| Rosiglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Rosiglitazone. |
| Acetohexamide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Acetohexamide. |
| Quinine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Quinine. |
| Miglitol | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Miglitol. |
| Chlorpropamide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Chlorpropamide. |
| Nateglinide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Nateglinide. |
| Pentamidine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Pentamidine. |
| Tolazamide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Tolazamide. |
| Repaglinide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Repaglinide. |
| Phenformin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Phenformin. |
| Sulfamethoxazole | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sulfamethoxazole. |
| Glyburide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Glyburide. |
| Glipizide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Glipizide. |
| Gliclazide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Gliclazide. |
| Tolbutamide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Tolbutamide. |
| Pioglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Pioglitazone. |
| Bromocriptine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Bromocriptine. |
| Gliquidone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Gliquidone. |
| Mitiglinide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Mitiglinide. |
| Sitagliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sitagliptin. |
| Sunitinib | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sunitinib. |
| Exenatide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Exenatide. |
| Mecasermin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Mecasermin. |
| Pramlintide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Pramlintide. |
| Glisoxepide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Glisoxepide. |
| Insulin aspart | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin aspart. |
| Insulin detemir | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin detemir. |
| Insulin glulisine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin glulisine. |
| Glymidine | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Glymidine. |
| AICA ribonucleotide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with AICA ribonucleotide. |
| Buformin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Buformin. |
| Vildagliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Vildagliptin. |
| Voglibose | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Voglibose. |
| NN344 | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with NN344. |
| AMG-222 | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with AMG-222. |
| Bisegliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Bisegliptin. |
| Alogliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Alogliptin. |
| Dapagliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Dapagliflozin. |
| Saxagliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Saxagliptin. |
| Liraglutide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Liraglutide. |
| Gosogliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Gosogliptin. |
| Linagliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Linagliptin. |
| Canagliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Canagliflozin. |
| Glibornuride | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Glibornuride. |
| Benfluorex | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Benfluorex. |
| Empagliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Empagliflozin. |
| Albiglutide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Albiglutide. |
| Dulaglutide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Dulaglutide. |
| Lobeglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Lobeglitazone. |
| Netoglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Netoglitazone. |
| Rivoglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Rivoglitazone. |
| Ciglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Ciglitazone. |
| Lixisenatide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Lixisenatide. |
| Insulin beef | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin beef. |
| Insulin degludec | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin degludec. |
| Insulin peglispro | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin peglispro. |
| Insulin tregopil | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin tregopil. |
| Ipragliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Ipragliflozin. |
| Dutogliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Dutogliptin. |
| Allicin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Allicin. |
| Tofogliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Tofogliflozin. |
| Ertugliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Ertugliflozin. |
| 2,4-thiazolidinedione | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with 2,4-thiazolidinedione. |
| Teneligliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Teneligliptin. |
| Omarigliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Omarigliptin. |
| Carmegliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Carmegliptin. |
| Gemigliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Gemigliptin. |
| Anagliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Anagliptin. |
| Evogliptin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Evogliptin. |
| Sotagliflozin | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Sotagliflozin. |
| Balaglitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Balaglitazone. |
| Remogliflozin etabonate | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Remogliflozin etabonate. |
| Carbutamide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Carbutamide. |
| Guar gum | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Guar gum. |
| Metahexamide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Metahexamide. |
| Semaglutide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Semaglutide. |
| Taspoglutide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Taspoglutide. |
| Englitazone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Englitazone. |
| Tirzepatide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Tirzepatide. |
| Gastric inhibitory polypeptide | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Gastric inhibitory polypeptide. |
| Mifepristone | The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Mifepristone. |
| Isoniazid | The serum concentration of Isoniazid can be decreased when it is combined with Loteprednol. |
| Cyclosporine | The risk or severity of adverse effects can be increased when Loteprednol is combined with Cyclosporine. |
| Digoxin | The risk or severity of adverse effects can be increased when Loteprednol is combined with Digoxin. |
| Acetyldigitoxin | The risk or severity of adverse effects can be increased when Loteprednol is combined with Acetyldigitoxin. |
| Deslanoside | The risk or severity of adverse effects can be increased when Loteprednol is combined with Deslanoside. |
| Digitoxin | The risk or severity of adverse effects can be increased when Loteprednol is combined with Digitoxin. |